- Home
- FRME vs OGN Comparison
FRME vs OGN Comparison
Compare FRME & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRME
- OGN
- Stock Information
- Founded
- FRME 1893
- OGN 1923
- Country
- FRME United States
- OGN United States
- Employees
- FRME N/A
- OGN N/A
- Industry
- FRME Major Banks
- OGN Biotechnology: Pharmaceutical Preparations
- Sector
- FRME Finance
- OGN Health Care
- Exchange
- FRME Nasdaq
- OGN Nasdaq
- Market Cap
- FRME 2.1B
- OGN 2.5B
- IPO Year
- FRME N/A
- OGN N/A
- Fundamental
- Price
- FRME $38.51
- OGN $9.68
- Analyst Decision
- FRME Buy
- OGN Hold
- Analyst Count
- FRME 4
- OGN 4
- Target Price
- FRME $44.75
- OGN $18.00
- AVG Volume (30 Days)
- FRME 349.2K
- OGN 3.8M
- Earning Date
- FRME 07-23-2025
- OGN 08-05-2025
- Dividend Yield
- FRME 3.73%
- OGN 0.83%
- EPS Growth
- FRME 2.61
- OGN N/A
- EPS
- FRME 3.55
- OGN 2.88
- Revenue
- FRME $615,411,000.00
- OGN $6,294,000,000.00
- Revenue This Year
- FRME $15.14
- OGN N/A
- Revenue Next Year
- FRME $5.03
- OGN $1.11
- P/E Ratio
- FRME $10.88
- OGN $3.36
- Revenue Growth
- FRME N/A
- OGN N/A
- 52 Week Low
- FRME $32.28
- OGN $8.01
- 52 Week High
- FRME $46.13
- OGN $23.10
- Technical
- Relative Strength Index (RSI)
- FRME 57.45
- OGN 53.19
- Support Level
- FRME $35.28
- OGN $9.73
- Resistance Level
- FRME $37.82
- OGN $10.30
- Average True Range (ATR)
- FRME 1.00
- OGN 0.35
- MACD
- FRME 0.14
- OGN 0.06
- Stochastic Oscillator
- FRME 94.81
- OGN 64.98
About FRME First Merchants Corporation
First Merchants Corp, through its subsidiaries, provides its customers with financial services delivered locally by bankers. It offers personal banking, business banking, real estate mortgage lending, cash management services, brokerage, wealth management, and insurance. The company reports in only one segment which is community banking.
About OGN Organon & Co.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.